Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPPORT: SABR and Pembrolizumab for Oligometastatic Renal Tumours
NCT02855203Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Oct 2016
- Primary completion
- May 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in renal cell carcinoma (RCC), sponsored by Peter MacCallum Cancer Centre. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02855203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02855203.